🇺🇸 FDA
Patent

US 9827223

Selective ablation of pain-sensing neurons by administration of a vanilloid receptor agonist

granted A61KA61K31/16A61K31/165

Quick answer

US patent 9827223 (Selective ablation of pain-sensing neurons by administration of a vanilloid receptor agonist) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Nov 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Nov 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61K, A61K31/16, A61K31/165, A61K31/167, A61K31/357